A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White/European Ancestry
A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White/European Ancestry
This is a first time in Asia (FTIA) study designed to evaluate the safety, tolerability, pharmacokinetic (PK) and immunogenicity of efimosfermin alfa to healthy participants of Chinese, Japanese, and White/European ancestry.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Auckland, New Zealand, 1010
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Participants who are generally healthy as determined by medical evaluation
- Body weight at least 50.0 kilograms (kg) for male participants or at least 45.0 kg for female participants
- Body mass index (BMI) within the range of 18.0 to 28.0 kilograms per square meter (kg/m^2) (inclusive)
- Male and female participants
- Participants of Chinese ancestry are eligible if born in mainland China, Hong Kong, or Taiwan, and descendant of 2 ethnic Chinese parents and 4 ethnic Chinese grandparents; and have lived outside China, Hong Kong, or Taiwan for less than 10 years at the time of screening.
- Participants of Japanese ancestry are eligible if born in Japan and descendant of 2 ethnic Japanese parents and 4 ethnic Japanese grandparents; and have lived outside Japan for less than 10 years at the time of screening.
- Participants of White/European ancestry are eligible if self-identified as being of White/European ancestry, (that is [i.e.], from the original peoples of Europe) irrespective of current place of residence; and descendant of 2 parents and 4 grandparents of White/European ancestry (i.e., from the original peoples of Europe) irrespective of place of birth or current place of residence.
Exclusion Criteria:
- History or presence of disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data.
- Current or chronic history of liver or biliary disease with the exception of Gilbert's syndrome or asymptomatic gallstones.
- History of pancreatic injury, pancreatitis or other pancreatic disease; history of Type one Diabetes Mellitus (T1DM) or positive glutamic acid decarboxylase auto-antibodies, or major Type two Diabetes Mellitus (T2DM) complications including severe gastroparesis and autonomic neuropathy.
- Abnormal blood pressure (defined as systolic Blood Pressure [BP] more than equal [>=]140 millimeters of mercury [mmHg] or diastolic BP >=90 mmHg measured based on the average of triplicate BP readings).
- History of metabolic bone disorders including osteoporosis, osteopenia, or osteomalacia.
- History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years.
- Alanine transaminase (ALT) more than (>)1.5 * upper limit of normal (ULN).
- Total bilirubin >1.5 * ULN
- Known bleeding disorder.
- History of immunodeficiency diseases, including a positive test result for human immunodeficiency virus (HIV).
- Corrected QT Interval using Fridericia's Formula (QTcF) >=450 millisecond (msec)(male) or >=470 msec (female) at Screening Visit based on the average of triplicate ECGs.
- Use of statins, other lipid lowering medications or hypertension medications unless on a stable dose for at least 3 months.
- Use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 30 days, whichever was longer; or longer if required by local regulations.
- Participants who have received native FGF21 or a FGF21 analog at any time in the past.
- Intended use of over the counter (OTC) or prescription medication (including herbal medications) within 7 days prior to dosing and for the duration of study participation.
- Live vaccine within 14 days prior to dosing and non-live vaccines for 7 days prior study dosing.
- Current enrolment or participation in another clinical trial within the last 30 days before signing consent of current study.
- Presence of hepatitis B surface antigen (HBsAg) or hepatitis C antibody at screening or within 3 months prior to the first dose of study intervention
- A positive pre-study drug/alcohol screen
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Efimosfermin alfa in participants of Chinese Ancestry
Healthy participants of Chinese ancestry will be randomized to receive efimosfermin alfa. |
Efimosfermin alfa to be administered |
|
Experimental: Efimosfermin alfa in participants of Japanese Ancestry
Healthy participants of Japanese ancestry will be randomized to receive efimosfermin alfa. |
Efimosfermin alfa to be administered |
|
Experimental: Efimosfermin alfa in participants of White/European Ancestry
Healthy participants of White/European ancestry will be randomized to receive efimosfermin alfa. |
Efimosfermin alfa to be administered |
|
Placebo Comparator: Placebo in participants of Chinese Ancestry
Healthy participants of Chinese ancestry will be randomized to receive Placebo. |
Placebo to be administered |
|
Placebo Comparator: Placebo in participants of Japanese Ancestry
Healthy participants of Japanese ancestry will be randomized to receive Placebo. |
Placebo to be administered |
|
Placebo Comparator: Placebo in participants of White/European Ancestry
Healthy participants of White/European ancestry will be randomized to receive Placebo. |
Placebo to be administered |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of participants with Adverse Events (AEs), treatment related AEs and serious adverse events (SAEs)
Time Frame: Up to 90 days
|
Up to 90 days
|
|
Number of participants with clinically significant changes in hematology, chemistry and urinalysis parameters
Time Frame: Up to 90 days
|
Up to 90 days
|
|
Number of participants with clinically significant changes in 12 Lead electrocardiogram (ECG)
Time Frame: Up to 90 days
|
Up to 90 days
|
|
Number of participants with clinically significant changes in vital signs
Time Frame: Up to 90 days
|
Up to 90 days
|
|
Area under the serum drug concentration versus time curve from time zero to the time of the last quantifiable concentration (AUC[0-t]) of efimosfermin alfa
Time Frame: Up to 90 days
|
Up to 90 days
|
|
Area under the serum drug concentration versus time curve from time zero extrapolated to infinity (AUC[0-inf]) of efimosfermin alfa
Time Frame: Up to 90 days
|
Up to 90 days
|
|
Maximum observed serum drug concentration, determined directly from the serum concentration-time data (Cmax) of efimosfermin alfa
Time Frame: Up to 90 days
|
Up to 90 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Time to maximum observed serum drug concentration (Tmax) of efimosfermin alfa
Time Frame: Up to 90 days
|
Up to 90 days
|
|
Apparent terminal phase half-life (t1/2) of efimosfermin alfa
Time Frame: Up to 90 days
|
Up to 90 days
|
|
Area under the serum drug concentration versus time curve from time zero to 90 days [AUC(0-90days)] of efimosfermin alfa
Time Frame: Up to 90 days
|
Up to 90 days
|
|
Time of last quantifiable plasma drug concentration (Tlast) of efimosfermin alfa
Time Frame: Up to 90 days
|
Up to 90 days
|
|
Apparent clearance (CL/F) of efimosfermin alfa
Time Frame: Up to 90 days
|
Up to 90 days
|
|
Apparent volume of distribution (Vz/F) of efimosfermin alfa
Time Frame: Up to 90 days
|
Up to 90 days
|
|
Area under the serum drug concentration versus time curve from time zero to 45 days [AUC(0-45days)] of efimosfermin alfa
Time Frame: Up to 45 days
|
Up to 45 days
|
|
Area under the serum drug concentration versus time curve from time zero to 60 days [AUC(0-60days)] of efimosfermin alfa
Time Frame: Up to 60 days
|
Up to 60 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: GSK Clinical Trials, GlaxoSmithKline
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 301158
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf
IPD Sharing Time Frame
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
IPD Sharing Access Criteria
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.